HPV-related oropharyngeal cancer prevalence in a middle eastern population using E6/E7 PCR.
Head and neck squamous cell carcinoma
Human papilloma virus
Lebanon
Middle East
Oropharyngeal cancer
Journal
Infectious agents and cancer
ISSN: 1750-9378
Titre abrégé: Infect Agent Cancer
Pays: England
ID NLM: 101276559
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
11
2019
accepted:
31
12
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
Given the paucity of data and widely variable rates that have been reported, the main objective of this study was to examine the prevalence of HPV-positivity in oropharyngeal squamous cell carcinoma (OPSCC) in Middle Eastern patients presenting to one of the region's largest tertiary care centers using polymerase chain reaction (PCR) amplification of the HPV E6/E7 oncogenes, a highly sensitive and specific method of detection. Medical charts and archived pathological specimens were obtained for patients diagnosed with biopsy proven oropharyngeal cancer who presented to the American University of Beirut Medical Center between 1972 and 2017. DNA was extracted from paraffin-embedded specimens and tested for 30 high-risk and low-risk papilloma viruses using the PCR-based EUROarray HPV kit (EuroImmun). A total of 57 patients with oropharyngeal cancer were initially identified; only 34 met inclusion/exclusion criteria and were included in the present study. Most patients were males (73.5%) from Lebanon (79.4%). The most common primary tumor site was in the base of tongue (50%), followed by the tonsil (41.2%). The majority of patients (85.3%) tested positive for HPV DNA. The prevalence of HPV-positivity amongst Middle Eastern OPSCC patients, specifically those from Lebanon, may be far greater than previously thought. The Lebanese population and other neighboring Middle Eastern countries may require a more vigilant approach towards HPV detection and awareness. On an international level, further research is required to better elucidate non-classical mechanisms of HPV exposure and transmission.
Sections du résumé
BACKGROUND
BACKGROUND
Given the paucity of data and widely variable rates that have been reported, the main objective of this study was to examine the prevalence of HPV-positivity in oropharyngeal squamous cell carcinoma (OPSCC) in Middle Eastern patients presenting to one of the region's largest tertiary care centers using polymerase chain reaction (PCR) amplification of the HPV E6/E7 oncogenes, a highly sensitive and specific method of detection.
METHODS
METHODS
Medical charts and archived pathological specimens were obtained for patients diagnosed with biopsy proven oropharyngeal cancer who presented to the American University of Beirut Medical Center between 1972 and 2017. DNA was extracted from paraffin-embedded specimens and tested for 30 high-risk and low-risk papilloma viruses using the PCR-based EUROarray HPV kit (EuroImmun).
RESULTS
RESULTS
A total of 57 patients with oropharyngeal cancer were initially identified; only 34 met inclusion/exclusion criteria and were included in the present study. Most patients were males (73.5%) from Lebanon (79.4%). The most common primary tumor site was in the base of tongue (50%), followed by the tonsil (41.2%). The majority of patients (85.3%) tested positive for HPV DNA.
CONCLUSION
CONCLUSIONS
The prevalence of HPV-positivity amongst Middle Eastern OPSCC patients, specifically those from Lebanon, may be far greater than previously thought. The Lebanese population and other neighboring Middle Eastern countries may require a more vigilant approach towards HPV detection and awareness. On an international level, further research is required to better elucidate non-classical mechanisms of HPV exposure and transmission.
Identifiants
pubmed: 31921331
doi: 10.1186/s13027-019-0268-z
pii: 268
pmc: PMC6945694
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1Subventions
Organisme : NIBIB NIH HHS
ID : R25 EB025787
Pays : United States
Informations de copyright
© The Author(s). 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Laryngol Otol. 2018 Jul;132(7):636-641
pubmed: 29954474
Sex Transm Infect. 2016 Feb;92(1):19-23
pubmed: 26071392
Asian Pac J Cancer Prev. 2013;14(10):6065-8
pubmed: 24289626
Head Neck. 2016 May;38(5):743-50
pubmed: 25521312
Clin Otolaryngol. 2006 Aug;31(4):259-66
pubmed: 16911640
Sex Health. 2016 Feb;13(1):10-21
pubmed: 26433493
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
J Clin Pathol. 2015 Nov;68(11):942-3
pubmed: 26112822
Laryngoscope. 2019 Jan;129(1):4-5
pubmed: 30194848
Curr Probl Cancer. 2018 Sep;42(5):466-475
pubmed: 30049422
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
Laryngoscope. 2019 Apr;129(4):877-882
pubmed: 30194702
Surg Pathol Clin. 2018 Sep;11(3):501-514
pubmed: 30190137
Am J Surg Pathol. 2012 Jul;36(7):945-54
pubmed: 22743284
Sci Rep. 2017 Dec 1;7(1):16715
pubmed: 29196639
Virol Sin. 2015 Apr;30(2):101-6
pubmed: 25910482
Ther Clin Risk Manag. 2018 Mar 27;14:617-626
pubmed: 29628765
Oral Oncol. 2018 Aug;83:147-153
pubmed: 30098771
Proc Natl Acad Sci U S A. 1994 May 10;91(10):4382-6
pubmed: 8183918
J Natl Cancer Inst. 2008 Mar 19;100(6):407-20
pubmed: 18334711
Head Neck. 2013 May;35(5):747-55
pubmed: 22267298
Sex Transm Infect. 2019 Aug;95(5):374-379
pubmed: 30636707
Otolaryngol Head Neck Surg. 2016 Jun;154(6):1034-40
pubmed: 26932972
Curr Oncol. 2009 Dec;16(6):5-7
pubmed: 20016740
Oral Oncol. 2014 Jun;50(6):565-74
pubmed: 24134947
Cancer. 2010 May 1;116(9):2166-73
pubmed: 20186832
Infect Agent Cancer. 2018 Jun 11;13:21
pubmed: 29942347